Cite
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
MLA
Santagostino, Elena, et al. “Safety and Efficacy of BAY 94-9027, an Extended-Half-Life Factor VIII, during Surgery in Patients with Severe Hemophilia A: Results of the PROTECT VIII Clinical Trial.” Thrombosis Research, vol. 183, Nov. 2019, pp. 13–19. EBSCOhost, https://doi.org/10.1016/j.thromres.2019.08.023.
APA
Santagostino, E., Lalezari, S., Reding, M. T., Ducore, J., Ng, H. J., Poulsen, L. H., Michaels, L. A., & Linardi, C. C. G. (2019). Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis Research, 183, 13–19. https://doi.org/10.1016/j.thromres.2019.08.023
Chicago
Santagostino, Elena, Shadan Lalezari, Mark T. Reding, Jonathan Ducore, Heng Joo Ng, Lone H. Poulsen, Lisa A. Michaels, and Camila C.G. Linardi. 2019. “Safety and Efficacy of BAY 94-9027, an Extended-Half-Life Factor VIII, during Surgery in Patients with Severe Hemophilia A: Results of the PROTECT VIII Clinical Trial.” Thrombosis Research 183 (November): 13–19. doi:10.1016/j.thromres.2019.08.023.